BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

581 related articles for article (PubMed ID: 15519905)

  • 1. The [3H]dofetilide binding assay is a predictive screening tool for hERG blockade and proarrhythmia: Comparison of intact cell and membrane preparations and effects of altering [K+]o.
    Diaz GJ; Daniell K; Leitza ST; Martin RL; Su Z; McDermott JS; Cox BF; Gintant GA
    J Pharmacol Toxicol Methods; 2004; 50(3):187-99. PubMed ID: 15519905
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A pharmacokinetic-pharmacodynamic model for the quantitative prediction of dofetilide clinical QT prolongation from human ether-a-go-go-related gene current inhibition data.
    Jonker DM; Kenna LA; Leishman D; Wallis R; Milligan PA; Jonsson EN
    Clin Pharmacol Ther; 2005 Jun; 77(6):572-82. PubMed ID: 15961988
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular determinants of dofetilide block of HERG K+ channels.
    Ficker E; Jarolimek W; Kiehn J; Baumann A; Brown AM
    Circ Res; 1998 Feb; 82(3):386-95. PubMed ID: 9486667
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Altering extracellular potassium concentration does not modulate drug block of human ether-a-go-go-related gene (hERG) channels.
    Limberis JT; Su Z; Cox BF; Gintant GA; Martin RL
    Clin Exp Pharmacol Physiol; 2006 Nov; 33(11):1059-65. PubMed ID: 17042915
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High affinity open channel block by dofetilide of HERG expressed in a human cell line.
    Snyders DJ; Chaudhary A
    Mol Pharmacol; 1996 Jun; 49(6):949-55. PubMed ID: 8649354
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Acidification alters antiarrhythmic drug blockade of the ether-a-go-go-related Gene (HERG) Channels.
    Dong DL; Li Z; Wang HZ; Du ZM; Song WH; Yang BF
    Basic Clin Pharmacol Toxicol; 2004 May; 94(5):209-12. PubMed ID: 15125690
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative pharmacology of guinea pig cardiac myocyte and cloned hERG (I(Kr)) channel.
    Davie C; Pierre-Valentin J; Pollard C; Standen N; Mitcheson J; Alexander P; Thong B
    J Cardiovasc Electrophysiol; 2004 Nov; 15(11):1302-9. PubMed ID: 15574182
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [3H]dofetilide binding in SHSY5Y and HEK293 cells expressing a HERG-like K+ channel?
    Finlayson K; Pennington AJ; Kelly JS
    Eur J Pharmacol; 2001 Feb; 412(3):203-12. PubMed ID: 11166283
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [3H]dofetilide binding to HERG transfected membranes: a potential high throughput preclinical screen.
    Finlayson K; Turnbull L; January CT; Sharkey J; Kelly JS
    Eur J Pharmacol; 2001 Oct; 430(1):147-8. PubMed ID: 11698075
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Investigating dynamic protocol-dependence of hERG potassium channel inhibition at 37 degrees C: Cisapride versus dofetilide.
    Milnes JT; Witchel HJ; Leaney JL; Leishman DJ; Hancox JC
    J Pharmacol Toxicol Methods; 2010; 61(2):178-91. PubMed ID: 20172036
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A mechanism for the proarrhythmic effects of cisapride (Propulsid): high affinity blockade of the human cardiac potassium channel HERG.
    Rampe D; Roy ML; Dennis A; Brown AM
    FEBS Lett; 1997 Nov; 417(1):28-32. PubMed ID: 9395068
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular determinants of inactivation and dofetilide block in ether a-go-go (EAG) channels and EAG-related K(+) channels.
    Ficker E; Jarolimek W; Brown AM
    Mol Pharmacol; 2001 Dec; 60(6):1343-8. PubMed ID: 11723241
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Block of HERG-carried K+ currents by the new repolarization delaying agent H 345/52.
    Amos GJ; Jacobson I; Duker G; Carlsson L
    J Cardiovasc Electrophysiol; 2003 Jun; 14(6):651-8. PubMed ID: 12875428
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fluorescently labeled analogues of dofetilide as high-affinity fluorescence polarization ligands for the human ether-a-go-go-related gene (hERG) channel.
    Singleton DH; Boyd H; Steidl-Nichols JV; Deacon M; Groot MJ; Price D; Nettleton DO; Wallace NK; Troutman MD; Williams C; Boyd JG
    J Med Chem; 2007 Jun; 50(13):2931-41. PubMed ID: 17536794
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacological inhibition of the hERG potassium channel is modulated by extracellular but not intracellular acidosis.
    DU CY; El Harchi A; Zhang YH; Orchard CH; Hancox JC
    J Cardiovasc Electrophysiol; 2011 Oct; 22(10):1163-70. PubMed ID: 21489024
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of the effects of metoclopramide and domperidone on HERG channels.
    Claassen S; Zünkler BJ
    Pharmacology; 2005 Apr; 74(1):31-6. PubMed ID: 15640612
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Allosteric modulators of the hERG K(+) channel: radioligand binding assays reveal allosteric characteristics of dofetilide analogs.
    Yu Z; Klaasse E; Heitman LH; Ijzerman AP
    Toxicol Appl Pharmacol; 2014 Jan; 274(1):78-86. PubMed ID: 24200993
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Novel potent human ether-a-go-go-related gene (hERG) potassium channel enhancers and their in vitro antiarrhythmic activity.
    Zhou J; Augelli-Szafran CE; Bradley JA; Chen X; Koci BJ; Volberg WA; Sun Z; Cordes JS
    Mol Pharmacol; 2005 Sep; 68(3):876-84. PubMed ID: 15976038
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular physiology and pharmacology of HERG. Single-channel currents and block by dofetilide.
    Kiehn J; Lacerda AE; Wible B; Brown AM
    Circulation; 1996 Nov; 94(10):2572-9. PubMed ID: 8921803
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of the rubidium efflux assay for preclinical identification of HERG blockade.
    Chaudhary KW; O'Neal JM; Mo ZL; Fermini B; Gallavan RH; Bahinski A
    Assay Drug Dev Technol; 2006 Feb; 4(1):73-82. PubMed ID: 16506891
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 30.